Patents Assigned to UM Pharmauji Sdn.BHD
-
Patent number: 9630932Abstract: The present invention provides trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitor compounds of formula (I), which may be therapeutically useful as DHODH inhibitors. wherein, R1, R2 and R3 have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting DHODH. The present invention also provides methods for synthesizing trisubstituted benzotriazole derivatives of formula (I). The present invention also provides pharmaceutical formulations comprising at least one of the DHODH inhibitor compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.Type: GrantFiled: February 24, 2014Date of Patent: April 25, 2017Assignees: UM PHARMAUJI SDN. BHD., AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Siva Sanjeeva Rao Thunuguntla, Subramanya Hosahalli, Satish Reddy Kunnam
-
Publication number: 20160200693Abstract: The present invention provides trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitor compounds of formula (I), which may be therapeutically useful as DHODH inhibitors. wherein, R1, R2 and R3 have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting DHODH. The present invention also provides methods for synthesizing trisubstituted benzotriazole derivatives of formula (I). The present invention also provides pharmaceutical formulations comprising at least one of the DHODH inhibitor compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: February 24, 2014Publication date: July 14, 2016Applicants: UM PHARMAUJI SDN. BHD., AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Siva Sanjeeva Rao Thunuguntla, Subramanya Hosahalli, Satish Reddy Kunnam
-
Patent number: 9353107Abstract: The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.Type: GrantFiled: July 1, 2013Date of Patent: May 31, 2016Assignees: Aurigene Discovery Technologies Limited, Um Pharmauji Sdn. Bhd.Inventors: Venkateshwar Rao Gummadi, Subramanya Hosahalli, Srinivas Nanduri, Girish Aggunda Renukappa
-
Publication number: 20150336949Abstract: The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.Type: ApplicationFiled: July 1, 2013Publication date: November 26, 2015Applicants: Um Pharmauji Sdn. Bhd., Aurigene Discovery Industrial AreaInventors: Venkateshwar Rao Gummadi, Subramanya Hosahalli, Srinivas Nanduri, Girish Aggunda Renukappa
-
Publication number: 20150183781Abstract: The present application relates to novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to prodrugs, derivatives, polymorphs, pharmaceutically acceptable salts and compositions comprising the said novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine compounds and their derivatives and their use in the treatment of various disorders.Type: ApplicationFiled: July 25, 2013Publication date: July 2, 2015Applicants: Um Pharmauji Sdn. Bhd., Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Subramanya Hosahalli, Srinivas Nanduri, Girish Aggunda Renukappa
-
Patent number: 9062002Abstract: The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: November 29, 2012Date of Patent: June 23, 2015Assignees: Aurigene Discovery Technologies Limited, UM Pharmauji Sdn. BHDInventors: Mohamed Takhi, Subramanya Hosahalli, Sunil Kumar Panigrahi, Muni Kumar Mahadari, Chandrashekar Reddy Kottam, Noorsaadah Abd Rahman, Rohana Yusof
-
Patent number: 9062075Abstract: The present invention relates to tetrahydropyridine derivatives of formula (1) which may be therapeutically useful as anti-bacterial agents, more particularly FabI inhibitors. in which X, Y, Z and ānā have the same meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FabI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: June 3, 2014Date of Patent: June 23, 2015Assignees: Aurigene Discovery Technologies Limited, UM Pharmauji Sdn. BHDInventors: Mohamed Takhi, Subramanya Hosahalli, Sunil Kumar Panigrahi
-
Publication number: 20140275019Abstract: The present invention relates to tetrahydropyridine derivatives of formula (1) which may be therapeutically useful as anti-bacterial agents, more particularly FabI inhibitors. in which X, Y, Z and ānā have the same meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FabI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: June 3, 2014Publication date: September 18, 2014Applicants: Aurigene Discovery Technologies Limited, UM Pharmauji Sdn.BHDInventors: Mohamed Takhi, Subramanya Hosahalli, Sunil Kumar Panigrahi, Muni Kumar Mahadari, Chandrashekar Reddy Kottam, Noorsaadah Abd Rahman, Rohana Yusof